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Acute myeloid leukemia (AML), the most common human 
aggressive leukemia, has a poor prognosis. Like many cancers, 
AML is characterized by differentiation arrest leading to ex-
pansion of leukemic stem cell (LSC) populations (also termed 
leukemia-initiating cells in transplantation experiments in 
immunodeficient mice). However, there is an incomplete 
understanding of where arrest occurs in the hemopoi-
etic differentiation hierarchy, which limits development of 
Our understanding of the perturbation of normal cellular differentiation hierarchies to create tumor-propagating stem cell 
populations is incomplete. In human acute myeloid leukemia (AML), current models suggest transformation creates leukemic 
stem cell (LSC) populations arrested at a progenitor-like stage expressing cell surface CD34. We show that in ∼25% of AML, 
with a distinct genetic mutation pattern where >98% of cells are CD34−, there are multiple, nonhierarchically arranged CD34+ 
and CD34− LSC populations. Within CD34− and CD34+ LSC–containing populations, LSC frequencies are similar; there are 
shared clonal structures and near-identical transcriptional signatures. CD34− LSCs have disordered global transcription pro-
files, but these profiles are enriched for transcriptional signatures of normal CD34− mature granulocyte–macrophage precur-
sors, downstream of progenitors. But unlike mature precursors, LSCs express multiple normal stem cell transcriptional regulators 
previously implicated in LSC function. This suggests a new refined model of the relationship between LSCs and normal hemo-
poiesis in which the nature of genetic/epigenetic changes determines the disordered transcriptional program, resulting in LSC 
differentiation arrest at stages that are most like either progenitor or precursor stages of hemopoiesis.
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novel therapeutic approaches in AML aimed at overcoming 
differentiation arrest.
In most human AML, and in the related preleukemic 
condition myelodysplastic syndrome, the initiating genetic 
mutation usually originates in a hemopoietic stem cell (HSC) 
or very early long-lived multipotent progenitor (MPP) cell 
(Jan et al., 2012; Corces-Zimmerman et al., 2014; Shlush et al., 
2014; Woll et al., 2014). This gives rise to expanded preleuke-
mic stem/progenitor cell populations with clonal advantage 
but permits differentiation, leaving the hemopoietic hierar-
chy relatively unperturbed, with subjects often having nor-
mal blood counts (Busque et al., 2012; Genovese et al., 2014; 
Jaiswal et al., 2014). Initiating mutations have been found in 
epigenetic regulators (e.g., TET2, IDH1, IDH2, DNMT3A, 
and ASXL1), the cohesin complex (MAU2 and SMC1A), and 
other AML-associated genes (e.g., NPM1; Busque et al., 2012; 
Jan et al., 2012; Corces-Zimmerman et al., 2014; Genovese et 
al., 2014; Shlush et al., 2014). After acquisition of an initiating 
mutation, it is unclear in which cell population subsequent 
mutations are acquired and how they perturb the hemopoi-
etic hierarchy. Nevertheless, the net effect of all genetic and 
epigenetic changes (i.e., leukemic transformation) is charac-
terized by disruption of the hemopoietic hierarchy and differ-
entiation arrest leading to the absence of mature blood cells.
In the fully transformed state, hemopoiesis is domi-
nated by multiple, expanded, immunophenotypically distinct 
LSC populations that generate bulk non-LSC populations. 
In AML samples in which the majority of leukemic cells 
express the normal hemopoietic stem/progenitor cell 
(HSPC) surface marker CD34, LSCs have been detected in 
both CD34+CD38− and CD34+CD38+ compartments (Bon-
net and Dick, 1997; Ishikawa et al., 2007; Taussig et al., 2010; 
Goardon et al., 2011) and more rarely in CD34− compart-
ments (Eppert et al., 2011; Sarry et al., 2011). By comparing 
immunophenotype and global gene expression profiles of 
CD34+ LSC-containing populations with normal HSPCs, we 
previously showed that human LSC populations were most 
closely related to normal progenitors, rather than HSCs, but 
had co-opted elements of a normal HSC expression signa-
ture (Goardon et al., 2011). This was consistent with earlier 
work in mouse models in which introduction of leukemic 
oncogenes into progenitors produced transplantable LSCs 
(Cozzio et al., 2003; So et al., 2003; Krivtsov et al., 2006; 
Kirstetter et al., 2008).
However, in ∼25% of human AML, >90% of leukemic 
cells do not express CD34. These samples are enriched for 
the NPM1 mutation (Falini et al., 2005; Martelli et al., 2010; 
Taussig et al., 2010). Here, LSC activity resides in a small 
CD34+ fraction and majority CD34− compartment (Martelli 
et al., 2010; Taussig et al., 2010; Sarry et al., 2011). However, 
it is unclear whether transformation creating leukemia-prop-
agating cells occurs initially in CD34+ progenitor-like cells or 
downstream in CD34− cells. It is also unclear whether CD34+ 
and CD34− LSC populations are hierarchically arranged and 
what the nature of the clonal relationships between CD34+ 
and CD34− LSCs is. At least three possible models for leuke-
mic hemopoiesis in CD34− AML exist (Fig. 1 A). In model 1, 
transformation associated with partial differentiation arrest 
and expansion of a cell compartment acquiring LSC func-
tion occurs at a CD34+ progenitor stage. These CD34+ LSCs 
partially differentiate into CD34− LSC populations and even-
tually into CD34− non-LSC bulk blast populations. Here, 
multiple, distinct, hierarchically arranged LSC populations 
exist. In model 2, transformation, expansion, and acquisition 
of the LSC function principally occurs at the CD34− precur-
sor stage (not previously described), with CD34 aberrantly 
expressed on a small subset of LSCs. Finally, in model 3, there 
could be a combination of models 1 and 2 in which some 
clones are transformed at the CD34+ progenitor stage and yet 
others are transformed at the CD34− precursor stage.
RES ULTS
CD34− AML has a distinctive mutational profile
We focused on samples in which ≤2% of mononuclear cells 
(MNCs) expressed CD34 (hereon referred to as CD34− AML). 
They accounted for 25% of 270 consecutive de novo AML 
samples (analyzed between January and July 2010; unpub-
lished data). We analyzed 49 consecutive CD34− AML samples; 
patient demographics, mean blast percentage, and percentage 
of MNCs expressing CD34+ (mean, 0.5%; range, 0.0–1.5%) 
are in Fig. 1 B and Table S1 A. 21/38 (55%) samples, in which 
karyotyping (segregated into prognostic groups; Grimwade et 
al., 2010) was available, had a normal karyotype (Fig. 1 B). We 
screened 24 genes (524 amplicons) by targeted resequencing 
for mutations commonly found in CD34− AML at a mean 
read depth of 3,500× (range of 100–13,000×; Fig. 1, B and 
C; and Table S1 B). Compared with The Cancer Genome 
Atlas (TCGA) cohort spanning the breadth of adult AML in 
which 62% of samples were CD34+ (Cancer Genome Atlas 
Research Network, 2013), our cohort had similar percentages 
of samples with normal karyotype (21/38 [55%] vs. 92/195 
[47%]). However, our cohort of CD34− AML samples was sig-
nificantly enriched for mutations in NPM1 (29/49 [59%] vs. 
54/200 [27%]; χ2 P < 0.0001) and IDH1/IDH2 (16/49 [33%] 
vs. 38/200 [19%]; χ2 P = 0.038) compared with the TCGA 
cohort (Fig. 1 D). Within NPM1 mutant samples, our cohort 
of CD34− AML samples compared with the TCGA cohort 
was enriched in IDH1/2 (48% vs. 22%; χ2 P = 0.014) and 
TET2 (17% vs. 4%; χ2 P = 0.034) and depleted for DNMT3A 
mutations (24% vs. 54%; χ2 P = 0.033). FLT3 mutations were 
at a similar frequency (48% vs. 50%; Fig. 1 D). In contrast to 
the TCGA cohort, we did not detect mutations in 14/24 most 
commonly mutated genes in AML. Finally, we compared the 
mutation profile in our 49-sample CD34− AML cohort with 
that of a distinct cohort of 84 sequential AML samples with 
>2% CD34+ blasts (Fig. 1, D and E). Once again, there was en-
richment of NPM1 mutations in CD34− AML (59% vs. 10%; 
χ2 P < 0.01; Fig. 1 E). Mutations in TET2 were also more fre-
quent in CD34− versus CD34+ AML (12% vs. 1%; P < 0.001). 
Finally, although there were fewer CD34+ AML samples with 
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Figure 1. CD34− AML models of differentiation arrest and genetics of samples. (A, left) Normal hemopoietic hierarchy. Initiating mutations in HSC 
or very early long-lived progenitors create preleukemic (Pre-L) stem cells with a clonal advantage. Model 1: mutations transform pre-LSCs into CD34+ pro-
genitor-like LSCs that differentiate into CD34− GM-pre–like LSCs, resulting in hierarchically arranged LSC populations. LSC populations then differentiate 
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IDH1/2 mutations (25%) compared with CD34− AML (33%), 
this was not statistically significant. Consistent with compar-
isons with the TCGA cohort, within NPM1 mutant AML, 
there were fewer TET2 (0% vs. 17%) in CD34+ AML versus 
CD34− AML. However, as the number of NPM1-mutated 
AML samples in our 84-sample CD34+ cohort was low (n = 
8), these differences did not reach statistical significance. In 
summary, compared with CD34+ AML, CD34− AML has a 
distinct, restricted mutational profile within the constraints of 
the sample size (n = 49) studied.
CD34− AML LSCs exist in CD34+ and CD34− populations  
and are not hierarchically arranged
28/49 samples had sufficient cells to test for LSC activity in 
NSG and/or NRG and/or NSGS mice. 11/28 samples se-
rially engrafted AML with NPM1 and/or FLT3 mutations 
(Table S2 A), allowing functional LSC identification. Because 
CD34− AMLs are enriched for more differentiated myelo-
monocytic/monocytic AML subtypes, we hypothesized that 
LSCs may express a combination of an immature (C-KIT/
CD117, commonly expressed on CD34− blasts; Nomdedeu 
et al., 2011) and mature (CD244) myelomonocytic marker 
(Table S1 A). Studying CD244 expression greatly facilitated 
later comparison of AML LSCs with normal CD34− cell 
populations (see the next section).
Samples with a higher proportion of CD117+ cells were 
more likely to engraft (Fig. 2 A). To pinpoint LSC activity, 
CD34+ and CD34− populations were purified from 8/11 en-
grafting samples in which sufficient cells were available for 
subsequent assays (sort purities are in Table S2, B and C). In 
seven out of eight cases, minor CD34+ populations had LSC 
activity (Fig. 2 B and Table S2 A). As the mean sort purity 
in the positive purification of the CD34+ LSC populations 
used in primary transplantation was 92% (Table S2 B), con-
taminating CD34− LSCs could make a minor contribution 
to engraftment. In CD34− fractions, LSC activity principally 
segregated with CD117 expression, especially when coex-
pressed with CD244 (eight out of eight samples; Fig. 2 B). En-
graftment was also seen from four out of five samples where 
the CD244−117+ fraction could be purified. CD117− cells 
engrafted in only two samples (#001 and #1037). Sample 
#1037 was exceptional, as all sorted cell fractions engrafted 
aggressively (Fig. 2, B and D). In sample #001, CD244+117− 
cells engrafted mice ∼80-fold less, with a 3.6-fold–increased 
cell dose compared with the CD244+117+ fraction (Fig. 2 C).
We next tested whether failure to engraft simply re-
flects low cell numbers injected rather than biological differ-
ences. Engrafting populations did so at cell doses equivalent 
to or lower than nonengrafting (i.e., non-LSC) populations 
(Fig. 2 C). Limit dilution assays showed similar LSC frequen-
cies between CD34+- and CD34−-engrafting subpopulations 
within a patient (Fig. 2 D and Table S2 D). CD117 expression 
in the CD34− compartment also purified LSCs (1.1–232-fold; 
mean, 27-fold), and the combined CD34−CD244+/−117+ 
fraction accounted for the majority of LSCs (mean, 72.9%; 
Table S2 D). CD34 expression also enriched for LSCs (14–
263-fold; mean, 133-fold), but CD34+ LSCs only contributed 
to 3.3% (range, 0.1–9.4%) of LSCs.
As CD34 expression marks normal HSPCs, we asked 
whether CD34+ and CD34− LSC populations were hierarchi-
cally arranged. Injected LSCs recapitulated the immunophe-
notype of the patient’s AML; CD244 and CD117 expression 
was maintained in engrafted cell populations in all eight sam-
ples (two representative samples in Fig. 2 E and full dataset in 
Table S2 E). Surprisingly, just as CD34+ LSCs generated both 
CD34+ and CD34− AML populations in primary recipient 
mice, CD34− LSCs also produced CD34+ and CD34− progeny 
(Fig. 2, E and F; and Table S2 E). Both CD34+ and CD34− pop-
ulations from primary recipients serially engrafted (Fig. 2 G) 
and generated CD34+ and CD34− cells in secondary recipi-
ents. Finally, by RNA sequencing (RNA-seq), only nine pro-
tein-coding genes of 15,539 expressed genes, including CD34, 
were significantly differentially expressed between CD34+ 
and CD34− LSC populations (P < 0.05; Fig. 2 H). Thus, in 
CD34− AML, these data are most compatible with function-
ally equivalent, nonhierarchically arranged CD34+ and CD34− 
LSC populations with near-identical transcriptomes (Fig. 2 I).
Identification of normal CD34− myeloid and erythroid 
precursors with limited progenitor potential
Next, we asked which normal BM populations most closely 
correspond to CD34− AML LSCs. Though myeloid pro-
into CD34− non-LSC blasts. Model 2: mutations transform pre-LSCs into CD34− GM-pre–like LSCs that then differentiate into CD34− non-LSC blasts. Here, 
CD34 would be aberrantly expressed on a small subset of LSCs. Model 3 combines models 1 and 2. Some clones acquire transforming mutations to create 
CD34+ progenitor-like LSCs that differentiate into CD34− GM-pre–like LSCs; other clones acquire transforming mutations to create CD34− precursor-like 
LSCs only. CMP, common myeloid progenitor; mat, mature granulocyte–monocytic effector cells; MEP, megakaryocyte-erythroid progenitor; MPP, MPP/
short-term HSC; PL, preleukemic; pre, granulocyte–monocyte precursors. (B) Characteristics of 49 CD34− AML samples: patient demographics, blast per-
centage, immunophenotype, karyotype, and mutational profile. (C) Karyotype and disease-associated nucleotide variants. The colored boxes denote either 
karyotype/risk stratification or mutation. No known disease-associated mutations were detected in CEB PA, CBL, ETV6, WT1, and Cohesin genes (see Table 
S1 B). (D, top) Frequency of the indicated mutations in our CD34− AML (n = 49), our CD34+ AML (n = 84), and our TCGA unselected AML (n = 200) sample 
cohorts. (Bottom) Mutations within NPM1 mutant samples in all three cohorts. n, number of samples. Statistically significant comparisons assessed by χ2 
tests are highlighted and marked with asterisks: *, P < 0.05; **, P < 0.01. (E) Distribution of NPM1 wild-type and mutant AML samples across a continuum of 
CD34 expression (assessed by flow cytometry as a percentage of MNCs: CD34+ AML, n = 84; CD34− AML, n = 49). The 2% threshold of CD34 expression used 
to select the CD34− AML cohort in this study is marked. The difference in percentage of NPM1 mutant samples between the two cohorts was statistically 
significant (**, P < 0.01). PTEN, phosphatase and tensin homologue.
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Figure 2. CD34+ and CD34− LSCs in CD34− AML are not hierarchically arranged and share near-identical RNA-seq profiles. (A) Mean percentage 
of cells with immunophenotypes indicated (as a percentage of Lin−CD34− MNCs) in engrafting and nonengrafting populations (total of 28 samples injected). 
The only populations significantly more abundant in engrafting samples were Lin−CD34−117+ and Lin−CD34−244+117+. *, P < 0.05; Student’s t test. Error 
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genitors have been studied, normal precursor/mature my-
eloid populations downstream of progenitors are poorly 
characterized, particularly with respect to surface markers 
used to fractionate AML samples. Distinct normal lineage 
(Lin)−CD34−244±117± BM populations (Fig. 3 A) were pu-
rified, characterized, and compared with normal CD34+ cells 
(Fig. 3, B–H; and Table S3). Normal CD34−244+117+ cells 
have promyelocyte morphology (Fig.  3  B), and consistent 
with this are CD11b−15+ cells (Fig. 3 C; van Lochem et al., 
2004). CD34−244+117− cells were a mix of mature granulo-
cytic cells (CD11b−15+, CD11b+15−, and CD11b+15+) and 
monocytes (CD11b+14+; Fig. 3, B and C). CD34−244−117+ 
cells are erythroblasts expressing high levels of CD71 (Fig. 3, 
B and D). CD34−244+117+ and CD34−244+117− cells ex-
pressed high levels of granulocyte–macrophage (GM) lin-
eage–affiliated genes SPI1/PU.1, MPO, CSF3R, IL3RA, 
ELA NE, and ITG AM, whereas CD34−244−117+ expressed 
erythroid-affiliated genes EPOR and SPTB (Fig. 3 E).
We then tested the functional output of normal CD34− 
fractions in liquid culture (Fig.  3  F). CD34+ cells were 
tested as a positive control. Whereas CD34+ cells gave rise 
to multilineage progeny with a peak output at day 21 (D21), 
CD34−244+117+ cells produced neutrophils (CD11b+15+) 
and monocytes (CD14+) peaking at D7. CD34+ cells produced 
2.4-fold more human cells than the CD34−244+117+ popula-
tion. Neither CD34−244+117− (mixed mature GM cells) nor 
CD34−244−117+ (erythroblasts) grew in liquid culture.
We next tested whether CD34− populations had pro-
genitor activity (Fig.  3 G). In contrast to CD34+ cells that 
gave erythroid and GM colonies peaking at D14, 
CD34−244+117+ cells gave rise to only short-lived, small 
macrophage or mixed GM colonies present only at D7 
(Fig. 3, G and H). CD34−244−117+ cells gave rise to small, 
distinct erythroid colonies at D7 that declined by D14. 
CD34−CD244+117− populations did not give colonies or cell 
clusters. No CD34− population gave rise to megakaryocyte 
colonies or expressed megakaryocyte-affiliated genes (PF4; 
Fig. 3 E; unpublished data). A previous study has shown that 
CD34−CD38−CD93hi populations have stem cell activity 
(Anjos-Afonso et al., 2013). The Lin−CD34−CD244±117± 
populations we purified were CD38−93dim and lacked stem 
cell activity in NSG mice (105 cells injected; unpublished 
data). Thus, normal Lin−CD34−117+ populations are GM 
(GM-pre; CD244+) and erythroid (CD244−) precursors seg-
regated by CD244 expression. Lin−CD34−244+CD117− cells 
are mature mixed GM cells (GM-mat).
CD34− AML LSCs express a disordered transcriptional 
profile with both HSPC and mature myeloid 
gene expression profiles
To understand where CD34− AML LSCs are arrested during 
hemopoietic differentiation, we compared global transcrip-
tional programs of LSCs with purified normal HSPC and pre-
cursor/mature populations (Table S4 A) by RNA-seq. We first 
used all 16,284 expressed genes and performed two-dimen-
sional principal component (PC) analysis (PCA; Fig. 4 A, left). 
This showed maturation of stem cells (HSCs)/MPPs through 
to more mature cells along PC1 and differentiation between 
GM and erythroid cells along PC2. This pattern of differenti-
ation was confirmed by an independent ANO VA approach to 
identify 9,369 genes (P < 0.05) differentially expressed among 
all normal populations. PCA showed relationships between 
normal populations using between 50 and 9,369 differentially 
expressed genes ranked by p-value (Fig. 4 A, right). As might 
bars represent SEM. (B) Primary engraftment (eight patients). Each symbol represents mean engraftment in one to six mice from the indicated population 
from one patient. Y axis, mean percentage of human (h)CD45+CD33+CD19− cell engraftment/total live MNCs. X axis, injected cell fraction. Red dashed 
line, engraftment threshold. Leukemic engraftment was confirmed by genetic analysis in each case. (C) Primary engraftment experiments where different 
numbers of cells were injected from sorted patient subpopulations annotated as engrafting (Eng) or nonengrafting (Non-eng). At least one engrafting 
subpopulation in each patient sample propagates leukemia at cell numbers lower than nonengrafting subpopulations. Each data point represents one in-
jected mouse. Asterisks indicate cell doses where multiple mice were injected with the same cell numbers. The number of asterisks indicates the number of 
different mice injected. (D) LSC frequency in sorted subpopulations calculated from limit dilution transplant assays. Error bars indicate the calculated 95% 
confidence interval. Data points without error bars indicate cell fractions where the threshold nonengrafting cell number was not achieved. Here, lowest 
injected cell numbers are shown (see Table S2 D). (E) Two points are made here: first, the patient’s CD34+ and CD34− populations when injected into mice 
produce both CD34+ and CD34− populations; second, the immunophenotype of the patient’s AML is recapitulated in the mouse. Two representative patient 
samples, #1037 and #875, from experiments with five different patient samples, show the immunophenotype in the patient sample. Blue arrows indicate 
CD244 and CD117 expression on CD34− AML cells. CD34+ (red boxes) and CD34− (blue boxes) subpopulations are flow sorted with purity for injection into 
mice. (Middle and bottom) Representative FACS analysis plots of engrafted human cells in mice. Mice injected with CD34+ cells or CD34− cells. In both 
cases, engrafting leukemic cells contain both CD34+ and CD34− populations and recapitulate the immunophenotype of the patient’s AML (see Table S2 E). 
(F) Box-whisker plots show percentage of human CD34+ leukemic cells in patient samples or primary recipients injected (Inj) with either CD34+ (samples 
from five patients injected into five mice) or CD34− populations (samples from five patients injected into 12 mice). The middle line is the median. Box limits 
are first and third quartile. Bars indicate minimum and maximum values. (G) Serial engraftment shows no hierarchy between CD34+ and CD34− LSCs. X 
axis, subpopulations from patient samples injected into primary mice; Y axis, mean percentage of human CD45+CD33+CD19− leukemia engraftment of total 
live MNCs in secondary mice when populations indicated on the left were injected. Each data point represents engraftment in one mouse (see Table S2 E). 
(H) RNA-seq data showing log2-fold change (logFC) in expression of all expressed genes (5 CD34+ and14 CD34− AML LSC samples on the y axis) plotted 
against mean log2 cpm (x axis). Statistically significant differentially expressed genes (P < 0.05) are annotated (red, up-regulated in CD34+ LSCs; blue, 
up-regulated in CD34− LSCs). (I) CD34+ and CD34− LSCs in CD34− AML generate both CD34+ and CD34− populations in primary transplants, each with 
leukemia-propagating activity in secondary transplants. n, number of patient samples studied per population.
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Figure 3. Normal marrow CD34−CD244±CD117+ populations are GM and erythroid precursors. (A, top) FACS plots with analysis gates showing 
lineage markers and CD34 expression, CD150/CD48 expression and forward scatter (FSC), and CD244 and CD117 expression in normal BM. (Bottom) Mean 
and SEM of each population as a percentage of MNCs. (B) Photomicrographs of FACS-sorted Lin−CD34−244+117+ (promyelocyte-like), Lin−CD34−244+117− 
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be expected, there is a greater dispersion of HSPC popu-
lations from different individual human BM donors when 
more genes are used. The 500 most differentially expressed 
genes (ANO VA 500) gave the best spatial segregation of nor-
mal populations and concordance between biological repli-
cates by both PCA (Fig. 4 A and Table S4 B) and hierarchical 
clustering (unpublished data). To study how comparable the 
ANO VA 500 gene set is to genes that make the biggest contri-
bution to PC1 and PC2 when using all genes, we selected 600 
genes with the most extreme loading scores in PC1 and PC2. 
After removal of duplicates, 490 of the unique 571 genes had 
HUGO Gene Nomenclature Committee (HGNC) IDs. We 
call this the PC-selected gene set. Comparison of PCAs with 
ANO VA and PC-selected genes showed similar separation 
of hemopoietic populations with preservation of the stem– 
mature and erythroid–GM axes (Fig. 4 B). Hierarchical clus-
tering using these two gene sets demonstrated greater donor 
effect and mixing of cell populations with the PC-selected 
490 gene set (Fig. 4 C). As the ANO VA 500 gene set gave a 
more precise clustering, we used this to define transcriptional 
profiles of the normal populations for the remainder of the 
analyses (Fig. 4, D and E; and Fig. 5). To validate our normal 
expression profiles, we generated gene expression signatures 
for each normal population, including GM-pre and GM-
mat cells, which had not previously been done. Signatures 
for HSPC populations were validated against published array 
signatures (Fig. 4, D and E; Laurenti et al., 2013).
We then used the ANO VA 500 gene in a three-dimen-
sional PCA but included expression data from CD34− AML 
LSCs (samples selected from those that serially transplant in 
immunodeficient mice are shown in Fig. 2). The stem–mat-
uration (PC2) and erythroid–GM (PC1) axes were preserved 
(Fig.  5  A). CD34− AML LSCs were positioned between 
normal GM-pre and GM progenitors (GMPs). This was in-
dependent of CD34 expression and NPM1 mutation status 
(Fig. 5 A). In bootstrap hierarchical clustering, LSCs clustered 
closest to normal GM-pre (Fig. 5 B). In contrast, CD34+ pro-
genitor-like LSC populations (samples from Goardon et al., 
2011) segregated away from CD34− AML LSCs and were 
nearest to normal lymphoid-primed MPPs (LMPPs)/GMPs, 
as previously described (Fig. 5, A and B; Goardon et al., 2011).
Next, we looked at the expression of ANO VA 500 
genes by hierarchically clustered heat maps in all normal 
populations, CD34− AML, and CD34+ progenitor LSC pop-
ulations (Fig. 5 C). A large proportion of genes showed a scat-
tered expression profile across normal HSCs/MPPs, LMPPs, 
GMPs, GM-pre, and GM-mat (Fig. 5 C, blue block) and both 
CD34− AML and CD34+ progenitor LSC populations. Only 
subsets of genes (Fig. 5 C, highlighted) showed preferential 
expression in GM-pre and GM-mat, CD34− AML LSC pop-
ulations, and HSPC and CD34+ progenitor LSC populations.
Given this, we specifically studied the gene expression 
of signatures of normal LMPP and GM-pre populations and 
LSC populations (Fig.  5  D). CD34+ progenitor-like AML 
LSCs compared with CD34− AML LSCs showed higher 
expression of LMPP/GMP signatures. In contrast, CD34− 
AML LSCs had higher expression of the normal GM-pre 
signature. These differences are specific, as there was low ex-
pression of the GM-mat signature in LSCs of both AML sub-
types (unpublished data).
Despite the close relationship between CD34− AML 
LSCs with normal GM-pre, we observed that CD34− AML 
LSCs are clearly distinct from normal populations. We hy-
pothesized that the distinctive transcriptional profile of 
CD34− AML LSCs is a hybrid, capturing a GM-pre profile 
(indicative of a stage of differentiation arrest) and elements 
of an HSC/early progenitor profile (associated with self- 
renewal). Gene set enrichment analysis (GSEA) showed 
CD34− AML LSCs are enriched for a normal HSC/MPP sig-
nature compared with the normal GM-pre cells. Conversely, 
unlike normal HSCs/MPPs, CD34− AML LSCs are strongly 
enriched for genes expressed in normal GM-pre, with gra-
dient enrichment for LMPP and GMP signatures (Fig. 5 E).
As CD34− AML LSCs express components of an HSC/
early progenitor transcriptional program, we asked whether 
LSCs express HSPC transcription factors (TFs). Using 547 
previously curated hemopoietic TFs (Novershtern et al., 
2011), CD34− AML LSCs occupy a unique position distinct 
from normal populations, suggesting that disorganization 
of the normal TF landscape likely results in differentiation 
arrest at a CD34−117+ GM-pre–like compartment. HOX 
genes (HOXB5, B3, B6, and A7), oncogenic TF MYCN, and 
(mature granulocytic series and monocytes), and Lin−CD34−CD244−117+ (erythroblast-like) stained with May-Giemsa-Grunwald. The box with dotted lines 
shows two amalgamated microscope fields from the same cytospin slide. Images are representative of three separate experiments using BM from three 
separate donors. Bars, 20 µm. (C and D) FACS-sorted Lin−CD34+ (n = 3 donors) and Lin−CD34− (CD244+117+ and CD244+117−, n = 6; CD244−117+, n = 4) pop-
ulations were tested for CD11b, CD15, and CD14 (C) and CD71 (D) expression. (E) Normalized gene expression (to GAP DH) of SPI1/PU.1, MPO, CSF3R, IL3RA, 
ELA NE, and ITG AM (expressed in GM lineage cells); EPOR and SPTB (expressed in erythroid cells); and PF4 in Lin−CD34−CD244+117+, Lin−CD34−CD244+117−, 
and Lin−CD34−CD244−117+ cells (n = 3 donors). *, P < 0.05; **, P < 0.01; two-sided Student’s t test. (F) Liquid culture output (human CD45+ cells and a 
percentage of total nucleated cells [TNC]) of 200 Lin−CD34+ and Lin−CD34− populations assessed by FACS studied on D7, 14, 21, and 28 (n = 3–4). CD56+, 
NK cells; CD19+, B cells; CD14+, monocytes; CD11b+15+, granulocytes; and CD11b−15+, promyelocytes.(G) Colonies produced when 300 cells from Lin−CD34+ 
and Lin−CD34− populations were plated in methylcellulose under myeloid colony formation conditions. Lineage affiliation was assessed by microscopy 
and confirmed in colony cytospins. E, erythroid; M, macrophage. Colonies were counted at D7 and D14 after plating (n = 5 donors). Error bars repre-
sent SEM. (H) Photomicrographs of representative D7 and D14 CFU-GM, D14 CFU-E colonies, and cytospins from the indicated populations (from five 
separate experiments using BM from five donors). Bars: (CFU-GM D7) 200 µm; (CFU-GM D14) 2,000 µm; (CFU-M/GM D14) 10 µm; (CFU-E D14) 100 µm; 
(CFU-E D14, right) 10 µm.
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stress- and cytokine-induced TFs CREB5, ATF3, and NFIL3 
(Fig. 5 F and Table S4 C) are likely to be key TF candidates 
mediating this disorganized landscape. In CD34− AML LSCs, 
111 TFs are coexpressed with GM lineage populations and 28 
TFs are coexpressed exclusively with HSCs/MPPs (Fig. 5 G). 
The 28 (a) include KMT2A (MLL), (b) select HOXA and 
HOXB MLL target genes (previously noted in NPM1- 
mutated human and mouse AML (Alcalay et al., 2005; Vassil-
iou et al., 2011; Spencer et al., 2015), and (c) include MEIS1, 
which cooperates with HOX genes in leukemogenesis 
(Wong et al., 2007), BMI1, and GATA2. All these TFs are 
associated with self-renewal, stemness, and development of 
AML. We then compared TF expressed in CD34+ progeni-
tor LSCs, normal HSCs/MPPs, and GM lineage–committed 
cells (Fig. 5 G). Seven TF genes are coexpressed between nor-
mal HSCs/MPPs and CD34+ progenitor LSCs. Of these, five 
(BMI1, MEIS1, HOXB3, B4, and B5) are also expressed in 
CD34− AML LSCs. Recent data have pinpointed HOXB5 as 
a marker of long-term mouse HSCs (Chen et al., 2016). Col-
lectively, CD34− AML LSCs express a hybrid stem-GM TF 
program. The data are consistent with diverse complements 
of AML mutations in CD34− AML directing a common ab-
errant HSC/MPP gene expression signature associated with 
self-renewal and/or block pathways that promote full dif-
ferentiation. Furthermore, there is a core set of five TFs ex-
pressed in all AML LSCs and normal HSCs/MPPs.
Next, we studied transcriptional differences between 
AML LSC and non-LSC populations (nonengrafting pop-
ulations in Fig.  2, B and C). Using the ANO VA 500 gene 
set from Fig. 4, within any one patient, non-LSCs were po-
sitioned further down the axis of GM differentiation than 
LSCs; i.e., they were more differentiated (Fig.  6 A). Com-
pared with non-LSC populations, CD34− AML LSC RNA 
profiles are significantly enriched for HSC/MPP signatures 
and depleted for GM-pre and GM-mat signatures (Fig. 6 B). 
Rank product analysis identified 125 genes differentially 
up-regulated in LSC populations and 175 genes more highly 
expressed in non-LSC populations (predicted false-positive 
[PFP] rate <0.05; Table S5). Using this 300-gene set in PCA, 
in PC1, normal HSPCs and a CD34− population of increas-
ing GM maturation were arrayed from left to right (Fig. 6 C) 
with the loading plot confirming expression of genes in more 
mature GM cells on the right (Fig. 6 D). Within any individ-
ual patient, LSCs lie well to the left of non-LSCs, confirm-
ing LSCs are less differentiated. A heat map of the 125 genes 
more highly expressed in LSC populations shows a gradient 
of expression (high in HSPCs and low in GM-mat), whereas 
genes more highly expressed in non-LSCs are most highly 
expressed in GM-mat (Fig. 6 E). Thus, transcriptome analysis 
supports a model in which non-LSC populations are more 
differentiated than LSC populations.
Clonal relationship of CD34+ and CD34− LSCs and expansion 
of LSC populations in CD34− AML
To determine whether clonal structures in CD34+ and 
CD34− populations varied and the size of each clone within 
the different leukemic hemopoietic compartments, we first 
performed exome sequencing (read depth of 30–100×) on 
all eight patient samples that engrafted. 48 high-confidence 
recurrent variants per sample were identified. On further 
filtering, this was reduced to 43 high-confidence AML- 
associated variants across all samples (Table S6, A–F). We then 
performed high-depth (100–10,000×) targeted resequencing 
of these 43 variants on populations and flow sorted single 
cells (Fig. 7, A–D, i; and Fig. 8, A and B, i). The details of the 
estimation of allele dropout (ADO) rates and determination 
of clonal structures (Fig. 7, A–D, ii; and Fig. 8, A and B, ii) 
are in the Estimation of false-negative homozygous reference 
calls in single-cell genotyping section of Materials and meth-
ods. We studied CD34+ and CD34−117± patient AML cells 
(Fig. 7, A–D, i–iii; and Fig. 8, A and B, i–iii) and AML cells 
from engrafted mice in six out of eight samples with sufficient 
material (Fig. 7, A–D, iv; Fig. 8, A and B, iv).
Initiating mutations were present in TET2 (Fig.  7, 
A–C, #880, #1037, and #044), IDH2 (Fig. 7 D), and NPM1 
(Fig. 8, A and B). Mutations in all three genes have been pre-
Figure 4. Gene expression of normal HSPC/precursor/mature populations by RNA-seq defines stem–mature and erythroid–GM differentiation 
axes in unbiased and selected gene sets. (A) PCA plots showing the position of different normal Lin−CD34+ HSPC (n = 3 donors), GM-pre (CD34−117+244+; 
n = 5 donors), GM-mat (CD34−117−244+; n = 4 donors), and erythroid precursor (Ery-pre; CD34−117+244−; n = 5 donors) populations using different num-
bers of genes: either all expressed genes (left), ANO VA-selected genes differentially expressed between the normal populations (P < 0.05), or 5,000, 500, or 
50 top differentially expressed genes (ranked by ANO VA p-value). The percentage of variance represented by each PC is shown. (B) A comparison of the ANO 
VA 500 gene set with the PC-selected 490 gene set by two-dimensional PCA. The stem–mature and GM–erythroid axes represented by the PCs are shown 
together with percentage of variance. Loadings plots are shown directly below the corresponding PCA, showing a selection of genes with the most extreme 
loadings scores in each PC. (C) Hierarchical clustering of ANO VA 500 and PC-selected 490 gene sets using 1,000 bootstrap (bs) permutation analyses. au = 
approximate unbiased p-values, which indicate the probability that the cluster is supported by the data. 100 = 100% probability that the cluster is correct. 
Height values measure dissimilarity expressed as (1 − [correlation coefficient]). Correlation coefficient of 1 = complete correlation. (D) Validation of gene 
expression signatures from our data for HSCs/MPPs, GMPs, common myeloid progenitors (CMPs), and megakaryocyte-erythroid progenitors (MEPs) with 
the signatures from a recent publication (Laurenti et al., 2013). In each Venn diagram, the number of genes in our signature (Quek) shared with those from 
Laurenti et al. (2013) are shown together with the total number of expressed genes in the two gene sets (bottom right corner). The likelihood of having 
shared genes expressed in both datasets out of total expressed genes is estimated using a χ2 test (χ-value p-value is indicated). (E) GSEA plots showing the 
enrichment of our HSC/MPP, common myeloid progenitor, megakaryocyte-erythroid progenitor, and GMP signatures against profiles of expressed genes in 
the indicated populations using published data (Laurenti et al., 2013). Normalized enrichment scores (NES) and FDR q-values (FDRq) are shown.
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Figure 5. GM-pre are the closest normal counterparts to CD34− AML LSCs by gene expression and disorganized transcriptional landscape. 
(A, left) Three-dimensional PCA separating normal HSPC/precursor/mature and CD34+ AML and CD34− AML LSC populations using the ANO VA 500 gene 
set (adjusted p-value ≤1.79 × 10−28; Table S4 B). The percentage of variance for each component is indicated. The relationship between NPM1-mutated 
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viously shown to give preleukemia (Corces-Zimmerman et 
al., 2014; Genovese et al., 2014; Jaiswal et al., 2014; Shlush et 
al., 2014). We could not detect any AML-associated mutations 
at variant allele frequencies (VAFs) consistent with preleuke-
mia in flow-sorted CD45+CD19+ B cells and CD45+CD3+ 
T cells available in five out of six samples (#044, #059, #875, 
#880, and #1037; unpublished data). Downstream of the ini-
tiating mutations, subclonal mutations were present in FLT3 
(five out of six cases; Fig. 7, A, B, and D; and Fig. 8, A and B), 
NPM1 (three out of six cases; Fig. 7, A–C), IDH1/2 (two out 
of six cases; Fig. 8, A and B), and the second allele of TET2 
(one out of six cases; Fig. 7 C). In all cases, acquisition of sub-
clonal mutations led to clone expansion.
In five out of six cases, the clones in the CD34+ and 
CD34− populations were shared. The exception was sample 
#059, (Fig. 7 D) in which the IDH2 mutant clone accounted 
for the entire CD34+ compartment. This observation dis-
proves model 3 (Fig. 1 A) as being generally applicable. In-
terestingly, the CD34+ compartment from #059 was the only 
CD34+ compartment of any sample that failed to engraft ei-
ther leukemia or normal hemopoiesis.
By using the abundance of CD34+- and CD34−117±-
sorted patient cells in Lin−MNCs (Table S6 G) and the fre-
quency of each clone within a sorted population (Fig. 7, A–D, 
i; and Fig.  8, A and B, i), we calculated the sizes of all the 
clones within the entire Lin−MNC compartment (Fig.  7, 
A–D, ii; and Fig. 8, A and B, ii). In all samples, the terminal 
clones accounted for the bulk of the Lin−MNCs (58–93%). 
The genetic basis for different clone sizes was unclear, 
although in general, clones with more mutations were larger.
By studying the sizes of the CD34+ and CD34−117± 
populations, we established where leukemia caused differenti-
ation arrest and determined the presence or absence of clones 
at different stages of leukemic differentiation and the size of 
clones at each stage of differentiation (Figs. 7 and 8, iii). In 
normal controls, CD34+ cells comprised 1–2% of Lin−MNCs, 
and the size of this population was similar (0.9–3.7%) in the 
leukemic samples. In contrast, the leukemic CD34−117+ pop-
ulation, regardless of CD244 expression, comprised 85–97% 
of Lin−MNCs (Table S6 G), whereas the normal counterpart 
population (GM-pre: CD34−244+117+, shown by RNA-
seq; Fig. 4) represents on average only 22.6% of Lin−MNCs 
(Fig. 3 A). The approximately fourfold expansion of the leu-
kemic CD34−117+ population occurred principally at the 
expense of more mature CD34−117− populations (which 
were reduced from 45% in normal BM [Fig. 3 A] to ≤14%), 
consistent with differentiation arrest in a CD34−117+ GM-
pre–like compartment that is either complete or partial.
Finally, we analyzed the clonal structures in human AML 
cells from mice injected with either CD34+ or CD34− popu-
lations (Fig. 7, A–D, iv; and Fig. 8, A and B, iv), which defined 
the clonal composition of experimentally determined LSCs. 
In four out of six samples, the most abundant clones were 
most likely to engraft (Fig.  7, samples #880, #1037, #044, 
and #059). This likely reflects increased cell numbers of the 
injected terminal clone but does not exclude increased fitness 
of a terminal clone to engraft. For example, in sample #059 
(Fig.  7 D), the majority of engrafted cells came only from 
one of the two FLT3 internal tandem duplication (ITD; 81 
bp) clones. Interestingly, in contrast to the weakly engraft-
ing 24-bp FLT3 ITD clone, the dominant engrafting 81-bp 
FLT3 ITD clone failed to differentiate into the most mature 
CD34−117− compartment. Here, complete differentiation ar-
rest of the 81-bp clone may be associated with more potent 
self-renewal and thus experimental stem cell function. Exome 
sequencing did not reveal other coding mutations segregating 
with the 81-bp clone that could account for this behavior.
In two out of six samples (Fig.  8, A and B), experi-
mentally determined LSC clonal architecture was more com-
plex. The CD34+ or the CD34−117+ population from sample 
(mut) CD34+ and CD34− LSCs and NPM1 wild-type (wt) CD34− LSCs (all in CD34− AML) is indicated. (Right) The loadings plot annotated with a selection 
of most variant genes is shown. (B) Bootstrap hierarchical clustering of normal and LSC populations using the same ANO VA 500 gene set using 1,000 
bootstrap (bs) permutations. (C) Heat map showing hierarchical clustering of ANO VA 500 genes and their expression by normal BM HSPC/precursor/mature, 
CD34+ AML, and CD34− AML LSC populations. Expression values are normalized per gene (by row) and are shown as a minimum–maximum scale (color 
bar). The blue block indicates genes with a scattered expression profile across normal, multiple normal, and LSC populations. The open rectangles highlight 
clusters of genes, with their gene names, which show preferential expression in GM-pre, GM-mat, and CD34− AML LSC populations and HSPC and CD34+ 
progenitor LSC populations. (D, right) Expression of the top 75 differentially expressed genes (rows = genes) in normal LMPPs and GM-pre populations in 
normal populations, CD34− AML, and CD34+ AML progenitor-like LSCs (indicated by colored horizontal bars; each column represents a different normal or 
LSC sample). Expression values are normalized per gene (by row) and are shown as a minimum–maximum scale (color bar). (Left) Mean expression of all 75 
genes in each normal and LSC population. Triple asterisks indicate highly significant differences in mean expression of 75 genes between CD34− AML and 
CD34+ progenitor-like AML (P < 0.001, corrected for multiple testing) in a test of 105 permutations of 75 randomly selected genes (of 16,284 expressed 
genes). Error bars represent SD. (E) GSEA of normal BM HSC/MPP, LMPP, GMP, and GM-pre signatures in preranked profiles (based on mean fold change), 
comparing CD34− LSCs with normal GM-pre and CD34− LSCs with normal HSCs/MPPs (all others). Normalized enrichment scores (NES) and FDR q-values 
(FDRq) are shown. All comparisons were statistically significant. (F) PCA using a curated list of 547 TFs adapted from Novershtern et al., 2011, showing the 
position of normal and CD34− AML LSC populations, with the associated loading plot. (G, top) Venn diagram of the overlap in differentially up-regulated 
genes encoding TFs in normal HSCs/MPPs, GM lineage–committed populations (GMP, GM-pre, and GM-mat), and CD34− AML LSCs. 28 TFs (of which 27 
have HGNC annotation) are up-regulated in both HSCs/MPPs and CD34− AML LSCs and are indicated. (Bottom) Combined analysis of the top Venn diagram 
with overlap in differentially up-regulated genes encoding TFs in normal HSCs/MPPs, GM lineage–committed populations, and CD34+ progenitor AML LSCs. 
Seven TFs are coexpressed in CD34+ progenitor AML LSCs and HSCs/MPPs. Of these, five (shown) are also expressed in CD34− AML LSCs. CMP, common 
myeloid progenitor; Ery-Pre, erythroid precursor; MEP, megakaryocyte-erythroid progenitor; prog, progenitor. 
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Figure 6. CD34− non-LSC populations are more differentiated compared with LSC populations. (A, left) PCA of normal populations and CD34− 
AML LSCs and non-LSC populations using the ANO VA 500 gene set (Fig. 4 A). The arrow shows the axis of normal myelomonocytic differentiation. (Right) 
PCA comparing LSCs and non-LSCs within five individual patients showing just the area shaded in gray on the main PCA plot on the left. CMP, common 
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#875 (Fig. 8 A) resulted in engraftment of the largest clone 
(NPM1/FLT3 D835Y/IDH1 mutant). However, single mice 
engrafted with different minor clones (NPM1/FLT3 N676K 
and NPM1/FLT3 D835Y). Moreover, the second most abun-
dant clone, NPM1/FLT3 A680V/IDH2, did not engraft. In 
sample #449 (Fig. 8 B), engrafting clones were either termi-
nal clones (present at 10–40% of MNCs) or an intermedi-
ate NPM1/IDH2 clone. In the CD34+ population, only the 
minor terminal clone (NPM1/FLT3 ITD; 81 bp) engrafted. 
This clone underwent further evolution on serial transplanta-
tion with loss of heterozygosity of the FLT3 wild-type allele. 
Five clones were present in CD34−CD117+ cells. In primary 
transplants, four out of five of these engrafted (mice #449.7–
449.10). With subsequent transplantation, there was both 
clonal selection (mice #449.16–449.24) and clonal evolution 
(mice #449.25–449.26 and #449.30–449.31) with loss of the 
wild-type IDH2 allele. Comparison of the clonal structure 
data from patients and engrafting mice consistently demon-
strated that the engrafted cells did not recapitulate the entire 
clonal structure in the patient, providing evidence for differ-
ent selective pressures for clonal expansion in man and mouse.
DIS CUS SION
CD34− AML is genetically distinct and enriched for NPM1 
and IDH1/2 mutations. Experimentally defined functional 
LSCs are present in the major CD34− and minor CD34+ 
fractions as noted previously (Martelli et al., 2010; Taussig et 
al., 2010). Our work extends prior work on CD34− AML by 
showing for the first time that the LSC frequencies are broadly 
equal in both compartments with the absence of hierarchy 
and, critically, are highly related transcriptionally. RNA-seq 
profiles of CD34+ and CD34− LSC populations differ only 
in the expression of eight genes, one of which is CD34. Thus, 
in contrast to normal hemopoiesis, CD34 expression is not a 
fixed immaturity-associated marker. Experimentally defined 
LSC function in the CD34− fraction is more commonly pres-
ent in CD117+ cells. The CD34−117+ compartment is greatly 
expanded with the virtual disappearance of mature myeloid 
cells. Most functional LSC activity lies within this population. 
Concordantly, experimentally defined CD34+ and CD34− 
LSC populations show similar clonal structures, although the 
preleukemic clone can be enriched or even exclusively pres-
ent in the CD34+ compartment.
A key problem in cancer biology is defining the stage 
in normal differentiation where tumor-propagating cells are 
partially or completely arrested. The key novel finding here 
is that by using expression signatures of normal HSPC and 
GM-mat populations, we showed that self-renewing CD34− 
AML LSCs, regardless of genetic mutation profile, are arrested 
very late in hemopoiesis, at a GM-pre stage, before terminal 
maturation. This is in contrast to LSCs in CD34+ progenitor 
AML (Goardon et al., 2011).
The refined comparison of gene expression profiles 
between normal HSPCs, GM-pre cells, GM-mat cells, and 
CD34− AML LSCs shows that CD34− AML LSCs express 
a small subset of HSC/early progenitor genes, including 28 
TFs normally expressed in normal HSCs/MPPs but not in 
normal GM-pre and GMP cells with oncogenic activity and 
implicated in stem cell function and myeloid leukemia, in-
cluding mouse models of Npm1-mutated myeloprolifera-
tive disease (Vassiliou et al., 2011) and Mycn-induced AML 
(Kawagoe et al., 2007). Furthermore, there is a core of only 
five normal HSC TFs expressed in both CD34+ progenitor 
LSCs and CD34− GM-pre LSCs.
Collectively, these findings suggest the cellular hierarchy 
in CD34− AML best fits model 2 in Fig. 1 A, where the sum 
of genetic and epigenetic changes leads to partial differen-
tiation arrest and marked expansion at a late GM-pre stage 
of hemopoiesis where cells acquire LSC function, and then 
LSCs further differentiate into non-LSCs.
LSCs have extensive self-renewal, proliferate, and fail to 
terminally differentiate. These properties could arise by differ-
ent means. For example, LSCs could have been most similar 
to HSCs with extensive self-renewal. However, as HSCs are 
normally quiescent, oncogenic mechanisms would have to 
provide proliferative drive and cause differentiation arrest. Al-
ternatively, LSCs could be similar to progenitors/precursors, 
allowing LSCs to use the proliferative programs intrinsic to 
these normal populations but requiring oncogenic changes to 
impart sustained self-renewal and differentiation arrest. Our 
current and previous observations (Goardon et al., 2011) are 
compatible with the latter hypothesis. Further work will de-
termine whether aberrant sustained self-renewal is mediated 
by the core set of five HSC/early progenitor TFs shared be-
tween normal HSCs/MPPs, CD34+ progenitor AML (Goar-
don et al., 2011), and CD34− GM-pre AML identified here, 
namely, HOXB3, B4 (Sauvageau et al., 1995; Antonchuk et 
al., 2002; Kyba et al., 2002; Oshima et al., 2011), B5 (Chen 
et al., 2016), MEIS1 (Ariki et al., 2014), and BMI1 (Lessard 
and Sauvageau, 2003; Park et al., 2003; Iwama et al., 2004). 
myeloid progenitor; Ery-Pre, erythroid precursor; MEP, megakaryocyte-erythroid progenitor. (B) Heat map of the normalized enrichment score (NES) from 
GSEA of normal HSC/MPP, GM-pre, and GM-mat signatures in profiles of LSC versus non-LSC populations in four patients (#001, #230, #875, and #880). 
Representative GSEA plots are from patient #001. (C) PCA showing the position of normal HSCs/MPPs, LMPPs, GM-pre, GM-mat, and CD34− AML LSCs 
and non-LSCs using 300 genes differentially expressed between CD34− LSCs and non-LSCs (from rank product analysis; PFP <0.05). (Top right and bottom) 
PCA of LSC and non-LSC populations in individual patients (#001, #059, #230, #875, and #880) analyzed with normal HSPC, GM-pre, and GM-mat cell 
populations. (D) Loadings plot of PCA in C. (E) Heat map of expression pattern of 125 genes with increased expression in CD34− AML LSC versus non-LSC 
populations (top) and 175 genes with increased expression in non-LSC versus CD34− AML LSC populations (bottom) in normal HSC/MPP, LMPP, GMP, 
GM-pre, and GM-mat populations. The color bar scale is as in Fig. 5 (B and D). (Right) Mean expression of the two gene sets in each population. Error bars 
represent SD. CPM, counts per million.
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Figure 7. Leukemic CD34+ and CD34− populations share clonal structures. (A–D) Partial differentiation arrest leads to expansion of an LSC-contain-
ing CD34−CD117+ population. (i) Clonal composition of FACS-purified populations using data from single-cell mutation–specific genotyping. (ii) Clonal hier-
archy of AML based on single-cell genotyping. Numbers within the circles indicate the percentage that each clone comprises within a Lin− MNC population. 
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However, it is also possible that some of these five TFs may 
also impose differentiation arrest, for example MEIS1 (Wong 
et al., 2007), possibly working with HOX and PBX (Ficara et 
al., 2013) partner proteins.
These studies also show that the disease-initiating clone 
is usually different in a human patient compared with that 
engrafting an immunodeficient mouse. A disease-initiating 
clone in a human is the clone with a first or disease-initiat-
ing mutation. This creates a preleukemic rather than leukemic 
state. When primary human AML cells are transplanted into a 
mouse, the clones that engraft are termed disease initiating in 
the mouse. These clones are usually fully transformed leuke-
mic cells with multiple mutations.
How do the clonal structures in our six cases of CD34− 
AML compare with those previously published? Single cell–
derived clonal structure data are available in only seven cases 
of primary human AML (Jan et al., 2012; Corces-Zimmerman 
et al., 2014; Klco et al., 2014). Additional population-based 
sequencing of preleukemic and leukemic compartments is 
available on another 20 samples (Jan et al., 2012; Corces-Zim-
merman et al., 2014; Shlush et al., 2014). Population-based 
data alone do not establish the precise order of mutation ac-
quisition but separate preleukemic from leukemic mutations. 
Within the limitations of the small datasets, what conclusions 
can be drawn? In our dataset, as in other AML cases, the ini-
tiating (or founder) mutations occur in TET2, NPM1, and 
IDH2. Combining all 27 cases (7 with single-cell data and 
20 samples with preleukemic and leukemic data), NPM1 
mutation was more commonly seen in leukemic as opposed 
to preleukemic cells (19/22 cases). More common preleu-
kemic mutations were in DNMT3A (11/15 cases), IDH1/2 
(13/16 cases), and TET2 (2/2 cases). Subclonal acquisition 
of mutations in NPM1, IDH1/2, and TET2 (the second al-
lele), documented here in CD34− AML, has also been seen 
in other AML samples (Jan et al., 2012; Corces-Zimmerman 
et al., 2014; Klco et al., 2014; Shlush et al., 2014). Both in 
our dataset and in the published dataset, FLT3 mutations are 
universally acquired as subclonal late events. In our samples, 
FLT3 ITD is associated with the greatest extent of leukemic 
expansion, predominantly in the CD34− GM-pre–like com-
partment. In summary, there are similarities in clonal structure 
between CD34− AML and other AMLs. The obvious differ-
ence is reduced frequency of the DNMT3A mutation in our 
sample set and its absence in samples in which we performed 
detailed studies. More generally, although some mutations are 
more commonly seen in a preleukemic phase and others in 
a leukemic phase, there is flexibility in the precise order in 
which mutations in most genes are acquired.
Clonal heterogeneity may also provide insight into how 
accurately widely used immunodeficient mice model clonal 
competition and stem cell function in patients. In three out 
of four samples studied (#059, 449, and 875), our data showed 
that only a subset of clones with LSC potential in the patient 
was captured in mice. This mirrors the only other recent pub-
lication in which engrafting potential did not match clonal 
composition in the patient (Klco et al., 2014). Moreover, the 
more frequent patient subclones are not necessarily the ones 
that engraft in mice. Finally, clonal competition in mice (sam-
ple #449) did not mirror clone fitness in the patient.
A related critical and as yet unanswered question is what 
are the genetic and epigenetic cell-autonomous determinants 
that dictate functional differences between clones with re-
spect to achieving clonal dominance in a patient (or experi-
mental in vivo models)? The type of analysis performed here 
will likely have to be extended with single-cell whole-ge-
nome sequencing, clonal epigenetic profiling, and single-cell 
RNA-seq to establish the full set of genetic and epigenetic 
differences between clones that could impact stem cell func-
tion in a patient and experimentally in vivo. The power of 
this type of analysis in sequential samples through therapy 
(and into relapse) will also provide an insight into the selec-
tive pressures imposed by therapy and therapy failure. Finally, 
clonal structure trees coupled with functional interrogation 
of clonal potential open the door to genome-editing strate-
gies to identify mutations required to sustain common clones 
and thus help define attractive therapeutic targets. These stud-
ies in AML will continue to provide an exemplar for similar 
studies in other cancers.
MAT ERI ALS AND MET HODS
Patient samples. BM or blood samples from normal donors 
and AML patients were obtained with informed consent and 
collected by research ethics committee–approved Biobanks 
(MDSBio Study, MREC 06/Q1606/110; Oxford Musculo-
skeletal Biobank, MREC 09/H0606/11: South Central Ox-
ford C Research Ethics Committee) and the AML17 clinical 
Numbers outside the circles indicate the number of cells called with each genotype. The asterisk indicates genotypes that were detected in less than three 
cells where they were called with <99% confidence because of ADO. Genotypes detected in more than two cells could be called with 99% confidence. (iii) 
The proportions of normal BM CD34+, GM-pre (CD34−117+), GM-mat (CD34−117−), other myeloid mature, and NK cell populations and erythroid precursors 
(Ery-pre; CD34−244+117+) are shown on the left for comparison with that observed in CD34− AML (right), showing expansion or contraction of populations. 
Within each leukemic population, the contribution of each clone is shown using data from panel i. Data are also in Table S6 G. (iv) Numbers of cells of 
FACS-purified populations injected into immunodeficient mice, estimated number of cells of each clone based on results in panel iii, and type of leukemic 
clones engrafted in each mouse are shown. Where more than one clone is detected in a mouse, circle size denotes major and minor clones. Engrafted 
clones may be serially engrafted in subsequent secondary and tertiary transplants. NE, no engraftment. Data from four patients and the number of single 
cells analyzed per population are shown. (A) Patient #880: CD34+, n = 18; CD34−CD117+, n = 20; CD34−CD117−, n = 20. (B) Patient #1037: CD34+, n = 16; 
CD34−CD117+, n = 18; CD34−CD117−, n = 20. (C) Patient #044: CD34+, n = 18; CD34−CD117+, n = 32; CD34−CD117−, n = 18. (D) Patient #059: CD34+, n = 
25; CD34−CD117+, n = 14; CD34−CD117−, n = 14. 
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trial (MREC 08/MRE09/29: Wales Research Ethics Com-
mittee). Karyotype and fluorescent in situ hybridization were 
carried out by hospital laboratories. MNCs were isolated by 
ficoll density gradient. In normal BM samples, CD34+ cells 
were purified using a CD34 Microbead kit and magnetic-ac-
tivated cell-sorting separation columns (Miltenyi Biotec). 
Unseparated CD34+- and CD34-deplete fractions were fro-
zen in 90% FCS/10% DMSO, stored in liquid nitrogen, and 
subsequently thawed on the day of the experiment.
Xenograft assay and LSC frequency assays. 10–14-wk-old 
NSG (NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ), NRG (NOD.
Cg-Rag1tm1Mom Il2rgtm1Wjl/SzJ), or NSGS (NOD.Cg-Prkdcscid 
Il2rgtm1Wjl Tg[CMV-IL3,CSF2,KIT LG]1Eav/MloySzJ; The 
Jackson Laboratory) mice were irradiated twice with 100 cGy 
4  h apart. Mice were injected intraperitoneally with 10% 
human immunoglobulin solution (1 mg/g of body weight; 
Privigen; CSL Behring) immediately after the second irradi-
ation. Cells were administered via intratibial injection within 
24 h of the second irradiation. Human CD45+33+19− (my-
eloid) or human CD45+33−19+ (B lymphoid) engraftment 
was analyzed by FACS and defined as ≥0.1% of live MNC 
gate. Experiments were performed in accordance with UK 
government–approved project license 30/2465. Engraftment 
Figure 8. Complex clonal hierarchies in samples where NPM1 mutation is acquired first also have expanded LSC-containing CD34−CD117+ 
populations. (A and B) NPM1-mutated clones underwent clonal selection and evolution in xenotransplanted mice. Data from two patients and the number 
of single cells analyzed per population. (A) Patient #875: CD34+, n = 35; CD34−CD117+, n = 35. (B) Patient #449: CD34+, n = 26; CD34−CD117+, n = 47. 
Panels i–iv are as in Fig. 7. Ery-pre, erythroid precursor; loh, loss of heterozygosity.
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was monitored by blood or marrow sampling from 12 wk 
after transplant, and mice were culled for cell harvesting be-
tween 12 and 28 wk. Experiments were performed in accor-
dance with UK government–approved project license 30/2465.
Calculating the frequency of LSCs. Percentages of sorted sub-
populations of each sample used in limit dilution assay exper-
iments were expressed as a percentage of live Lin−MNCs. The 
95% confidence intervals for stem cell frequency were calcu-
lated using L-Calc software (STE MCE LL Technologies) 
based on a Poisson distribution.
FACS protocols. FACS analysis was performed on either a 
Cyan ADP (Dakocytomation) or LSR Fortessa flow cytome-
ter (BD). Flow sorts were performed on an Aria III SORP 
(BD). Antibodies used for depletion of cells expressing lineage 
markers; purification of normal CD34+ HSPCs, CD34− cells, 
CD34− AML samples, and CD34+ progenitor AML samples; 
mouse engraftment analysis; and MS5 co-culture experiments 
(MS5) are included in the the next paragraph.
Antibodies used in the lineage depletion cocktail for 
purification of (a) CD34− normal and CD34− AML sam-
ples were anti-CD2, anti-CD3, anti-CD4, anti-CD8a, anti- 
CD10, anti-CD19, anti-CD20, and anti-CD235a and of 
(b) CD34+ normal BM and CD34+ AML samples were an-
ti-CD2, anti-CD3, anti-CD4, anti-CD7, anti-CD8a, anti- 
CD11b, anti-CD14, anti-CD19, anti-CD20, anti-CD56, 
and anti-CD235a. Normal CD34+ stem/progenitor popu-
lations and CD34+ AML samples were analyzed and sorted 
using lineage depletion and antibodies to CD34, CD38, 
CD90, CD123, and CD45RA. Normal CD34− BM and 
CD34− AML samples were lineage depleted using mag-
netic bead lineage depletion (anti–mouse IgG microbeads; 
Miltenyi Biotec) before analysis and sorted using antibod-
ies to CD34, CD150, CD48, CD244, and CD117. Normal 
subpopulations were analyzed for lineage affiliation using 
antibodies to CD11b, CD14, CD15, and CD71. Engraft-
ment was assayed using antibodies to human CD45, CD19, 
and CD33. BM harvested from engrafted mice was analyzed 
and sorted using antibodies to human CD45, CD33, CD19, 
CD34, CD150, CD48, CD244, and CD117. See Fig. S1 for 
FACS gating strategies.
In vitro myeloid/B lymphoid and NK cell differentiation as-
says. 5 × 104 MS5 stromal cells/well were plated onto gelati-
nized 24-well plates in MEM-α (Thermo Fisher Scientific) 
with 10% FCS (Thermo Fisher Scientific), 10 ng/ml throm-
bopoietin, FLT3-ligand, granulocyte CSF, IL-2, IL-15, 20 ng/
ml CSF (PeproTech), and 10−7 M DUP697 (Cayman Chem-
ical) 12 h before addition of 200 flow-sorted marrow cells. 
The medium was half-changed weekly. Harvested cells were 
FACS analyzed at D7, D14, and D28.
Colony assays. For progenitor colony–forming assays, 300 
cells were plated in duplicate in 1.2 ml MethoCult GFH4435 
(STE MCE LL Technologies). The rest of the procedure was 
performed as previously described (Goardon et al., 2011).
Gene expression by dynamic arrays. 500 cells (>99% purity) 
were FACS sorted into 96-well plates with 10 µl of reaction 
buffer (5 µl of 2× reaction mix [CellsDirect; Thermo Fisher 
Scientific], 1 µl RT/Taq Mix [CellsDirect], 0.4 µl of water, 
0.1 µl RNase inhibitor [SUP ERase-In; Thermo Fisher Sci-
entific], and 2.5 µl of a mix of 0.2× TaqMan gene expres-
sion assays [Thermo Fisher Scientific]). Reverse transcription 
and specific target preamplification conditions were 15 min 
at 50°C, 2 min at 95°C, 22 cycles of 15 s at 95°C, and 4 min 
at 60°C. Preamplified samples were diluted 1:4 and analyzed 
on a 48.48 dynamic array (Fluidigm). PCR cycling condi-
tions were 10 min at 95°C, 40 cycles of 15  s at 95°C, and 
60 s at 60°C. All reactions were performed in three technical 
replicates. Data were analyzed using the ΔCt (cycle thresh-
old) method; results were normalized to GAP DH expression 
and expressed as the mean expression level relative to GAP 
DH. TaqMan assays were obtained from Thermo Fisher Sci-
entific: GAP DH (Hs02758991_g1), ELA NE (Hs00975994_
g1), EPOR (Hs00959427_m1), MPO (Hs00924296_m1), 
PF4 (Hs00427220_g1), SPI1 (Hs02786711_m1), SPTB 
(Hs01024103_m1), CSF3R (Hs00167918_m1), ITG AM 
(Hs00355885_m1), and IL3RA (Hs00608141_m1).
Nucleic acid manipulation. DNA extraction was performed 
using a DNeasy Blood and Tissue extraction kit (69506), and 
RNA extraction was performed using an RNeasy Micro kit 
(74004; QIA GEN). Whole-genome amplification (WGA) 
was performed using 3–10 ng of extracted genomic DNA or 
3 × 103–104 sorted AML cells using an amplification kit (Il-
lustra GenomiPhiV2; GE Healthcare). Nucleic acids were an-
alyzed and quantified using Qubit assay (Invitrogen) or the 
appropriate Bioanalyser chip (Agilent Technologies).
Exome sequencing. Libraries for whole-exome sequencing 
(WES) were prepared using either a SeqCap EZ (v3; Nim-
blegen) or a SureSelect All Exon Enrichment kit (V5; Agilent 
Technologies) and sequenced on HiSeq2000 (Illumina) using 
100-bp paired-end reads. Raw reads were mapped using a 
Burrows-Wheeler aligner (Stampy) to the NCBI Human 
Reference Genome Build hg19 (Lunter and Goodson, 2011). 
Aligned reads that passed standard quality filters were submit-
ted for variant calling using VarScan2 (Koboldt et al., 2009) 
for both single nucleotide variants (SNVs) and indels. Variants 
were annotated with Annovar.
Targeted resequencing. Libraries were created from pooled, 
indexed amplicons generated using Fluidigm Access Array 
Primers (see online supplemental material) using Fluidigm 
Access Array. 500 amplicons were multiplexed per gDNA 
sample and sequenced on MiSeq (Illumina) using 150-bp or 
250-bp paired-end reads. Reads were mapped using Stampy 
onto hg19. Aligned reads that passed standard quality filters 
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were submitted for variant calling using VarScan2 for both 
SNVs and indels, and Pindel (Spencer et al., 2013) was used 
to optimize detection of longer indels, e.g., ITD in FLT3. 
Variants were annotated with Annovar software.
Mutation detection pipeline. Putative variants were filtered 
using the following parameters: (a) WES: minimum coverage, 
15; minimum variant frequency, 0.01; minimum read depth in 
variant, 2; and p-value of 0.05; and (b) targeted resequencing: 
minimum coverage, 100; minimum variant frequency, 0.01; 
minimum read depth in variant, 5; and p-value of 0.05. As 
CEB PA had low coverage in next generation sequencing, 
data mutation analysis for this gene was performed separately 
(see the CEB PA mutation analysis section).
In both WES and targeted resequencing datasets, ad-
ditional exclusion criteria for variants were (a) variants pre-
dicted to result in a silent amino acid change; (b) known 
polymorphisms present in human variation databases (Exome 
Sequencing Project 6500; 1,000 genomes; SNP database) at 
a population frequency >0.0014 (reflecting the population 
incidence of myeloid disease) except for when the variant 
was a known somatic variant in the Catalogue of Somatic 
Mutations in Cancer (COS MIC); (c) variants present in at 
least one of the two T cell germline controls with a VAF >10; 
(d) variants noted to be rare in hematopoietic disease (docu-
mented in less than two hematopoietic samples in COS MIC) 
but which occurred in more than one of our AML cohort 
samples; and (e) 1-bp indels present adjacent to regions of 
more than four homopolymer bases. Variants were included 
on the basis of (a) previous documentation as a somatic mu-
tation in hematopoietic samples in COS MIC or (b) novel 
variants in ASXL1 or TET2 genes (not previously reported), 
which have high-impact structural change (nonsense, delete-
rious missense, and indels) not found in either T cell germline 
controls or in human variation databases with a frequency 
>0.0014. Putative variants were further validated by visual-
ization using the Integrated Genome Viewer.
NPM1 quantitative PCR from genomic DNA. To investigate 
engraftment of bulk and sorted populations from NPM1 mu-
tant AML samples, genomic DNA was extracted from mouse 
blood or BM (bulk or sorted populations) and subjected to 
quantitative PCR. Reactions were performed in triplicate 
and run on the quantitative PCR platform (ABI7900; Ap-
plied Biosystems) using standard conditions. Albumin gene 
(ALB; human and mouse) and NPM1 exon 12 assays (mu-
tant allele and wild-type control) were used to assess the per-
centage of engraftment, calculated using the ΔCt method, 
as described previously (Jovanovic et al., 2013). Primers and 
probe sequences for NPM1 have been previously published 
(Gorello et al., 2006; Chou et al., 2007): NPM1 common 
forward, 5′-GTG TTG TGG TTC CTT AAC CAC AT-3′; 
NPM1 mutation A reverse, 5′-CTT CCT CCA CTG CCA 
GAC AGA-3′; NPM1 mutation D reverse, 5′-CCT CCA 
CTG CCA GGC AGA-3′; NPM1 mutation I reverse, 5′-CTT 
CCT CCA CTG CCT TAC AGA GA-3′; NPM1 control re-
verse, 5′-TCT TAA AGA GAC TTC CTC CAC TGC-3′; and 
NPM1 common probe (FAM/minor groove binder), 5′-
TTT TCC AGG CTA TTC AAG AT-3′.
CEB PA mutation analysis. The entire coding sequence of the 
CEB PA gene was amplified by PCR in three overlapping 
fragments, and the products were analyzed by WASP-family 
verprolin homologous protein (WAVE)–denaturing 
high-performance liquid chromatography (Transgenomic) as 
previously described (Green et al., 2010).
Single-cell genotyping. Single cells were flow sorted into 96-
well plates containing 4 µl phosphate-buffered saline. WGA 
was performed using the Single Cell RepliG kit (QIA GEN). 
In brief, after cell lysis, alkali denaturation, and neutralization, 
a master mix containing Phi29 polymerase, deoxyribose nu-
cleoside triphosphate, and random oligonucleotide primers 
was added. WGA was performed at 30°C for 8 h followed 
by heat inactivation. Diluted (1:20) amplified DNA was used 
in single-plex PCR with an Access Array system (Fluidigm) 
using primers relevant to the sample. Barcoding and sequenc-
ing oligonucleotides were added by PCR, and sequencing 
was performed on MiSeq (Illumina). Raw sequences were 
aligned on BaseSpace using ISA AC (Raczy et al., 2013). Ap-
proximately 94% of reads had Phred scores >30. A thresh-
old of 100 reads was set for analysis inclusion, except for 
NPM1 exon 12, where a threshold of 1,000 reads was used 
to improve specificity.
VAF estimation of FLT3 ITD and other mutations in bulk cells 
and single cells. For estimation of VAF of FLT3 ITD se-
quences in AML samples, we used Pindel (Spencer et al., 
2013). We searched fastq files for 20-bp sequences specific for 
the ITD or unaffected by the ITD. The VAF of the FLT3 ITD 
was the number of identified ITD sequences/reference se-
quences. The same approach was used for single-cell data. For 
VAF estimation of known SNVs in single-cell data, we took 
a similar approach by creating 20-bp reference and muta-
tion-specific sequences.
Establishing thresholds for detection of variants in single-cell 
data. Thresholds for detecting a mutation and false-positive 
rates for each mutation were established by analyzing single 
cells from samples that were wild type for mutations of inter-
est, for example, sample #449, #1037, and #059, which are all 
wild type for FLT3 D835Y, A680V, and N676K.
Estimation of false-negative homozygous reference calls in 
single-cell genotyping. A major issue in single-cell genotyp-
ing is ADO, where one allele fails to amplify. This can result in 
a heterozygous allele being called homozygous. The phenom-
enon of ADO is well known to occur when performing 
DNA amplification from low quantities of starting material. 
Previous studies performing single-cell genotyping have esti-
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mated ADO rates of 4–15% (Treff et al., 2011; Hou et al., 
2012) using RepliG. To calculate the ADO rate, we performed 
the following experiments. Heterozygous and homozygous 
SNVs (synonymous or nonsynonymous) were identified in 
AML-bulk genomic DNA. These SNVs were then geno-
typed in single cells. In 80/760 amplicons (i.e., a frequency of 
0.105 or 10.5%), heterozygous SNVs were erroneously called 
homozygous reference alleles in single-cell genotyping. This 
means that in a population in which two mutations have been 
called (mutations A and B), there is a 10.5% chance that a 
single cell in which only a single mutation (e.g., mutation A) 
is detected may actually have both mutations (mutations A 
and B). Furthermore, if there are four mutations in the popu-
lation (mutations A, B, C, and D), the chance that a single cell 
in which only mutation A is detected but actually has two 
mutations is 3 × 10.5% = 31.5%.
Where multiple cells are found with only one muta-
tion, the chance that none of the cells are truly of a single 
mutant clone is (10.5%)n, where n is the number of cells with 
only a single mutation. For any single cell, the ADO for the 
full complement of mutations present in that cell depends on 
the total informative SNVs (and thus the number of ampli-
cons used for genotyping). Thus, the predicted rate at which 
any single cell would have ADO events in two different loci 
would be (0.105)2 = 0.011 (or 1.1%). The false-negative rate 
of 10.5% per amplicon was used to estimate the likelihood of 
the presence or absence of small clones.
Determination of clonal structures. Each single cell was as-
sessed for detection or nondetection of mutations relevant to 
that patient sample. To be included for analysis, each cell had 
≥100× coverage of all relevant amplicons. We assigned the 
most likely sequence of acquisition of mutations based on the 
genotype identified in cells. For example, where mutations 
A–E were identified in a sample, discrete cells with genotypes 
A, AB, ABC, ABD, ABCD, and AE may be called. In most 
cases, the sequence of acquisition, e.g., A→AB, is clear. How-
ever, the sequence of acquisition of mutations during the 
transition, for example, from AB to ABCD may not be clear 
because of ADO, i.e., the sequence of acquisition may be 
AB→ABC→ABCD or AB→ABD→ABCD. In such cases, 
intermediate genotypes represented by the most cells will be 
more likely to be true. In all cases, models of clonal structures, 
which require the least number of discrete mutational steps 
required, will be represented (Potter et al., 2013), although we 
accept that alternative structures, including ones where the 
same mutation is acquired twice, are possible.
Analysis of raw RNA-seq data. Duplicates were removed, and 
reads were filtered for uniquely mapping reads (MAPQ >3) 
using SAMtools (version 0.1.19; Li et al., 2009). Data analyses 
were performed using the R software environment for statis-
tical computing (version 3.0.1). Gene-level read summariza-
tion was performed using the R package genomic ranges, and 
gene expression analysis was conducted using edgeR 
(McCarthy et al., 2012). For read counts and PCAs, read 
counts were normalized as counts per million (cpm) and log2 
transformed. Sequencing data were submitted to ArrayEx-
press (accession no. E-MTAB-2672).
Analysis of gene expression data. We used a filtering strategy 
to eliminate nonexpressed or only marginally expressed genes 
from the 59,689 genes defined in Ensembl. We retained the 
genes that had a cpm >2 in at least half of the samples of at 
least one of the experimental conditions considered. Thus, we 
retained 16,284 genes, of which 13,461 had an HGNC anno-
tation, for further analysis.
We generated gene expression profiles by computing 
differential gene expression. Our experimental design in-
cluded comparisons of (a) populations using an ANO VA 
approach, (b) populations using a selection approach based 
on genes with the greatest contribution to variance in PCA 
of total genes (PC-selected), (c) selected populations against 
other selected populations (e.g., CD34− AML LSCs vs. non-
LSCs using rank product analysis), and (d) selected popula-
tions against the mean of the remaining populations (e.g., to 
create expression signatures). Genes present in more than one 
signature were removed.
Differential gene expression was computed using gen-
eralized linear models. Where appropriate, we included the 
donor as an additive covariate to correct for donor-specific 
effects. We calculated the log2-fold changes, p-values of differ-
ential expression, and the false discovery rate (FDR)–adjusted 
p-values of differential expression of all genes in all the profiles.
PCA and permutation cluster analysis was performed 
using Pvclust, with all ANO VA-selected genes (9,369 genes; 
FDR <0.05) and then the top 5,000, 500, and 50 genes 
with normal stem, progenitor, precursor, and mature popu-
lations. For permutation analysis, we performed analysis with 
up to 10,000 bootstrap samplings but observed no further 
change in clustering after 1,000 samplings. We selected the 
500-gene set (corresponding to genes with p-values <2.28 
E-30) for further analysis of combined data from normal 
and AML samples. We also performed heat map hierarchical 
clustering using Hclust.
As set out in Fig. 5 D, the statistical significance of dif-
ferences in mean expression between CD34− AML LSCs, 
CD34+ progenitor-like LSCs, and normal populations in 
terms of normal LMPP and GM-pre signatures was estab-
lished by permutation testing. Fold-change values of 75 ran-
domly selected genes (from the gene set of 16,284 genes) 
were assessed over 100,000 samplings and compared with the 
observed expression difference. The p-values of these com-
parisons were <0.001 (corrected for multiple testing), in-
dicating that the differences between the overall expression 
of the 75-gene sets between CD34−AML LSCs and CD34+ 
progenitor LSCs were highly significant.
GSEA. We used GSEA (Subramanian et al., 2005) to test 
enrichment of specific population expression signatures in 
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expression profiles. Population-specific signatures were com-
puted from a subset of the gene expression values described 
in the previous section by selecting genes that are up-reg-
ulated with an FDR-adjusted p-value <0.05. The Ensembl 
gene identifiers of these genes were translated into HGNC 
symbols, and the 250 genes with the highest fold changes 
were selected as gene sets for GSEA.
Comparison with published datasets. To estimate the con-
cordance of our population-specific gene signatures (see 
the previous section at FDR-adjusted p-value <0.05) with 
published data from equivalent published cell populations 
(ArrayExpress accession no. E-MTAB-2672; Laurenti et 
al., 2013), we conducted GSEA with our gene signatures 
against the Laurenti profiles.
Online supplemental material. Fig. S1 shows FACS 
analysis and sorting strategies. Table S1 shows data on 
immunophenotype and karyotypic and genetic analysis of 
CD34− AML samples. Recurrent nucleotide variants detected 
by targeted resequencing and/or WES are filtered according 
to parameters set out in the Mutation detection pipeline 
section. Table S2 shows FACS data of xenotransplantation 
assays. Table S3 shows sort purities of normal BM MNC 
fractions used for in vitro culture assays. Table S4 shows 
RNA-seq analysis of normal BM and CD34− AML samples. 
Table S5 lists 300 significantly differentially expressed genes 
between CD34− LSC and non-LSC populations analyzed 
by rank product analysis (PFP <0.05). Table S6 contains data 
from bulk- and single-cell genotyping. Online supplemental 
material is available at http ://www .jem .org /cgi /content 
/full /jem .20151775 /DC1.
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Figure S1. FACS analysis and sorting strategies. (A) FACS gating of CD34− AML samples. (B) Two different sort strategies of CD34− AML samples. 
(C) Sort strategy of normal CD34+ stem/progenitor populations. FSC, forward scatter; SSC, side scatter; MEP, megakaryocyte-erythroid progenitor; CMP, 
common myeloid progenitor
S27JEM
Table S1 is provided as an Excel file and shows data on: (A) immunophenotype and (B) karyotypic and genetic analysis of 
CD34− AML samples. Recurrent nucleotide variants detected by targeted resequencing and/or whole-exome sequencing are 
filtered according to the parameters set out in Materials and methods.
Table S2 is provided as an Excel file and shows FACS data of xenotransplantation assays: (A) serial AML engraftment of un-
sorted and sorted CD34+ and CD34− populations in CD34− AML, (B and C) sort purities of AML populations used in xenotrans-
plantation, (D) estimation of LSC frequency of engrafting subpopulations, and (E) immunophenotype of engrafted leukemia 
cells compared with the primary patient AML sample.
Table S3 is provided as an Excel file and shows sort purities of normal BM MNC fractions used for in vitro culture assays.
Table S4 is provided as an Excel file and relates to RNA-seq experiments: (A) the sort purities of normal and AML samples, (B) 
ranked loadings scores in the first two PCs of 500 genes selected by ANO VA analysis, and (C) 547 TF genes ranked by load-
ings scores in PC1 and PC2.
Table S5 is provided as an Excel file and lists 300 significantly differentially expressed genes between CD34− LSC and non-LSC 
populations analyzed by rank product analysis (PFP <0.05).
Table S6 is provided as an Excel file and contains data from bulk and single-cell genotyping. VAF of recurrent, AML-associated 
mutations in samples: (A) #880, (B) #1037, (C) #044, (D) #059, (E) #875, and (F) #449. Table S6 G shows the frequencies 
of sorted populations for single-cell genotyping (as percentage of Lin− MNCs) and their sort purities.
